BR112021000312A2 - Vacina, peptídeos, polipeptídeo, polinucleotídeo, vetor de vacina, método de tratamento ou prevenção da infecção por map ou da condição ou sintoma associado à infecção por map e kit - Google Patents

Vacina, peptídeos, polipeptídeo, polinucleotídeo, vetor de vacina, método de tratamento ou prevenção da infecção por map ou da condição ou sintoma associado à infecção por map e kit Download PDF

Info

Publication number
BR112021000312A2
BR112021000312A2 BR112021000312-6A BR112021000312A BR112021000312A2 BR 112021000312 A2 BR112021000312 A2 BR 112021000312A2 BR 112021000312 A BR112021000312 A BR 112021000312A BR 112021000312 A2 BR112021000312 A2 BR 112021000312A2
Authority
BR
Brazil
Prior art keywords
polypeptide
amino acid
seq
acid sequence
map
Prior art date
Application number
BR112021000312-6A
Other languages
English (en)
Portuguese (pt)
Inventor
John Hermon-Taylor
Original Assignee
Hav Vaccines Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hav Vaccines Limited filed Critical Hav Vaccines Limited
Publication of BR112021000312A2 publication Critical patent/BR112021000312A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112021000312-6A 2018-07-11 2019-07-10 Vacina, peptídeos, polipeptídeo, polinucleotídeo, vetor de vacina, método de tratamento ou prevenção da infecção por map ou da condição ou sintoma associado à infecção por map e kit BR112021000312A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1811382.9A GB201811382D0 (en) 2018-07-11 2018-07-11 Vaccine
GB1811382.9 2018-07-11
PCT/GB2019/051933 WO2020012177A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis

Publications (1)

Publication Number Publication Date
BR112021000312A2 true BR112021000312A2 (pt) 2021-04-13

Family

ID=63273113

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000312-6A BR112021000312A2 (pt) 2018-07-11 2019-07-10 Vacina, peptídeos, polipeptídeo, polinucleotídeo, vetor de vacina, método de tratamento ou prevenção da infecção por map ou da condição ou sintoma associado à infecção por map e kit

Country Status (14)

Country Link
US (2) US12186382B2 (https=)
EP (1) EP3820507A1 (https=)
JP (2) JP2021524485A (https=)
KR (1) KR20210033490A (https=)
CN (1) CN113329765A (https=)
AU (1) AU2019301899A1 (https=)
BR (1) BR112021000312A2 (https=)
CA (1) CA3105763A1 (https=)
GB (1) GB201811382D0 (https=)
IL (1) IL280070B2 (https=)
MA (1) MA53131A (https=)
MX (1) MX2020013924A (https=)
SG (1) SG11202100120TA (https=)
WO (1) WO2020012177A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
WO2026041756A1 (en) 2024-08-21 2026-02-26 Hav Vaccines Limited Treatment of crohn's disease by mycobacterium avium subsp. paratuberculosis agent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
US5225324A (en) 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
AU2006277828B2 (en) 2005-08-09 2012-02-02 Hav Vaccines Limited Immunogenic constructs
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
CA2839865A1 (en) 2011-05-19 2012-11-22 University Of Central Florida Research Foundation, Inc. Microbe detection via hybridizing magnetic relaxation nanosensors
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
US20160228528A1 (en) 2013-01-28 2016-08-11 Janssen Sciences Ireland Uc A single or multistage mycobacterium avium subsp. paratuberculosis subunit vaccine
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic

Also Published As

Publication number Publication date
MA53131A (fr) 2021-05-19
US12186382B2 (en) 2025-01-07
AU2019301899A1 (en) 2021-01-14
CA3105763A1 (en) 2020-01-16
IL280070B2 (en) 2024-04-01
WO2020012177A1 (en) 2020-01-16
GB201811382D0 (en) 2018-08-29
SG11202100120TA (en) 2021-02-25
JP2021524485A (ja) 2021-09-13
JP2024153666A (ja) 2024-10-29
IL280070B1 (en) 2023-12-01
US20210338791A1 (en) 2021-11-04
IL280070A (en) 2021-03-01
EP3820507A1 (en) 2021-05-19
CN113329765A (zh) 2021-08-31
KR20210033490A (ko) 2021-03-26
US20250152691A1 (en) 2025-05-15
MX2020013924A (es) 2021-03-02

Similar Documents

Publication Publication Date Title
ES2271449T3 (es) Compuestos para inmunoterapia y diagnostico de la tuberculosis.
KR20210092762A (ko) 아프리카 돼지 열병 바이러스에 대한 면역원성 조성물
US20250152691A1 (en) Immunogenic composition for paratuberculosis
JP2002503683A (ja) 結核の免疫療法および診断のための化合物および方法
HUE026171T2 (en) A method for treating, preventing and detecting Helicobacter infection
JP2003524021A (ja) 悪性中皮腫の診断および治療のための組成物および方法
JPH09509568A (ja) 精子透明帯結合タンパク質の自己抗原エピトープに対応する精子抗原
US5656451A (en) OspE, OspF, and S1 polypeptides in borrelia burgdorferi
JP2005523704A (ja) 連鎖球菌感染症に対するワクチン接種用キメラcamp因子
CA2593643C (en) A plasmodium vivax hybrid circumsporozoite protein and vaccine
JP4160640B2 (ja) クラミジア・ニューモニエ由来の表面露出タンパク質
US6596281B1 (en) Mycobacterium tuberculosis specific proteins and genes, mixtures of antigens and uses thereof
BRPI0708959A2 (pt) genes e proteìnas de brachyspira hyodysenteriae e uso dos mesmos para diagnóstico e terapia
BRPI0613168A2 (pt) molécula de polipeptìdeo isolada; molécula de ácido nucléico isolada; vetor ou plasmìdeo; célula hospedeira; anticorpo; proteìna de fusão; método para estimular uma resposta imunogênica especìfica à tb em um indivìduo ou para prevenir ou reduzir a gravidade de doença causada pela tb; método para monitorar o tratamento da doença causada pela tb em um indivìduo; método de diagnóstico de doença causada pela tb em um indivìduo; método de distinção entre a doença causada pela tb e a imunidade à doença causada pela tb em um indivìduo; método para detecção da infecção por m. tuberculosis em uma amostra biológica; composição; kit para diagnóstico da presença ou da ausência de infecção por m. tuberculosis em uma pessoa; e composição farmacêutica
CA2617506C (en) Immunogenic constructs useful for treating mycobacterium avium subspecies paratuberculosis (map) infection
AU6875798A (en) 76 kDa, 32 kDa, and 50 kDa helicobacter polypeptides and corresponding polynucleotide molecules
JP4102186B2 (ja) グループbストレプトコッカスのbvh−a2及びbvh−a3抗原
US6716591B1 (en) B. burgdorferi polypeptides
WO2002079240A2 (en) Intimins for the prevention or treatment of infections: i
JP2000510339A (ja) インビボで発現されるB.burgdorferiポリペプチド
WO1997039020A2 (en) Antigenic sequences of a sperm protein and immunocontraceptive methods
WO2012013191A2 (en) Recombinant proteins as vaccines for protection against disease induced by infection with mink astrovirus
BRPI0804859A2 (pt) peptìdeos sintéticos para a obtenção de polìmero proteìco para imunização contra leishmaniose, produtos e seus usos